Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
NCT07096453Phase 2Recruiting
- Sponsor
- University of Minnesota
- Start
- Oct 2025
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of IgPro10 in cytomegalovirus infection (CMV), sponsored by University of Minnesota. Started Oct 2025; status: recruiting.
02
Drugs
IgPro10
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07096453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096453.